siparadigm.com

What It Is

siParadigm is a medical technology and laboratory platform focused on precision oncology diagnostic informatics, with CLIA and CAP certifications. It is committed to providing comprehensive biomarker analysis for cancer patients through multi-omics approaches—genomics, transcriptomics, proteomics, and more—helping shift cancer diagnosis from traditional morphology-based methods to precision diagnostics based on molecular profiling.

Core Dimensions

• Core Functional Modules: The platform offers a wide range of testing services, including solid tumor genomic analysis (500+ genes or 50-gene panels), DeepSight™ liquid biopsy (523 or 50 ctDNA genes), hematopathology, and hereditary cancer risk assessment. Its most distinctive feature is the siFISH TC/PC platform, an AI-enabled digital interpretation workspace that supports hospital pathologists in reading the professional component (PC) of FISH tests. It provides both manual digital analysis and computer-assisted analysis modes, significantly improving diagnostic efficiency.
• Team Collaboration and Permissions: The siFISH TC/PC model intelligently separates the technical component (TC, where siParadigm performs the wet lab work and imaging) from the professional component (PC, controlled by hospital pathologists), ensuring hospitals retain full diagnostic control. It also supports one-click escalation of complex cases to global consultation.
• Third-Party Integration and Deployment: Cloud-based deployment supports seamless ordering and result access through a HIPAA-compliant web portal or EMR interface. The siFISH platform also integrates with LIS (Laboratory Information Systems) and includes built-in DocuSign e-signature capabilities for structured report generation.
• Data Security and Compliance: It strictly follows healthcare industry standards, holds CLIA and CAP certifications, and meets HIPAA compliance requirements to protect patient data privacy.

Pricing

siParadigm uses a per-project pricing model and offers “unbundled” options: Comprehensive Profiling ($$$, 500+ gene NGS and companion diagnostics), Focused Profiling ($$, fewer than 50 genes plus selected FISH/IHC), and single-site testing ($). The platform provides insurance prior authorization assistance and has a financial hardship assistance program, claiming that more than 90% of patients will not pay more than in-network rates.

Pros and Cons

• Pros: Broad multi-omics testing coverage; AI-assisted FISH interpretation reduces TAT to 2–3 days; simultaneous tissue and liquid testing helps address tumor heterogeneity; free consultation support from molecular pathologists and oncologists.
• Cons: Specific pricing is not publicly disclosed; services are mainly geared toward U.S.-based healthcare institutions; the AI interpretation platform may involve a learning curve for some pathologists.

Who It’s For

Primarily designed for oncologists, hospital pathologists, and healthcare institutions—especially departments that want to retain in-house control over specialized diagnostics such as FISH while improving diagnostic efficiency and precision treatment guidance.

Access in China

Unknown. As a U.S.-based clinical laboratory, siParadigm mainly serves healthcare institutions in the United States and Puerto Rico. Direct access to its official website or use of its SaaS platform by users in China may be limited by cross-border medical data compliance requirements and network factors.